Atara Biotherapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Atara Biotherapeutics, Inc. (Nasdaq: ATRA) to present at 42nd Annual J.P. Morgan Healthcare Conference, showcasing its T-cell immunotherapy and EBV T-cell platform for cancer and autoimmune diseases.

THOUSAND OAKS, Calif.--(BUSINESS WIRE)-- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will present at the 42^nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11, at 9:45 a.m. PST / 12:45 p.m. EST in San Francisco, California.

A live webcast of the presentation will be available by visiting the Investors and Media section of atarabio.com. An archived replay of the webcast will be available on the Company's website for 30 days following the live presentation.

About Atara Biotherapeutics, Inc.

Atara is harnessing the natural power of the immune system to develop off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions that can be rapidly delivered to patients within days. With cutting-edge science and differentiated approach, Atara is the first company in the world to receive regulatory approval of an allogeneic T-cell immunotherapy. Our advanced and versatile Epstein-Barr virus (EBV) T-cell platform does not require T-cell receptor or HLA gene editing and forms the basis of a diverse portfolio of investigational therapies that target EBV, the root cause of certain diseases, in addition to next-generation AlloCAR-Ts designed for best-in-class opportunities across a broad range of hematological malignancies and B-cell driven autoimmune diseases. Atara is headquartered in Southern California. For more information, visit atarabio.com and follow @Atarabio on X (formerly known as Twitter) and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240104354568/en/

Investor and Media Relations:

Alex Chapman

Vice President, Corporate Communications & Investor Relations

(805) 456-4772

achapman@atarabio.com

Jason Awe, Ph.D.

Senior Director, Corporate Communications & Investor Relations

(805) 217-2287

jawe@atarabio.com

Source: Atara Biotherapeutics, Inc.

FAQ

What is the company presenting at the 42nd Annual J.P. Morgan Healthcare Conference?

Atara Biotherapeutics, Inc. (Nasdaq: ATRA) will present its T-cell immunotherapy and EBV T-cell platform for cancer and autoimmune diseases.

When will the presentation take place?

The presentation will take place on Thursday, January 11, at 9:45 a.m. PST / 12:45 p.m. EST.

Where can I watch the live webcast of the presentation?

The live webcast will be available by visiting the Investors and Media section of atarabio.com.

How long will the archived replay of the webcast be available?

The archived replay of the webcast will be available on the Company's website for 30 days following the live presentation.